Psychopharmacology and Psychiatry Updates Lurasidone's Therapeutic Window: Is Less More?
Oct 13, 2025
Join Kristin Raj, a psychiatrist and faculty contributor to the Psychopharmacology Institute, as she delves into the intriguing findings of a recent meta-analysis on lurasidone for bipolar depression. Discover why lower doses (40-60mg) may actually be more effective and safer than higher doses, potentially changing prescribing practices. Kristin discusses the risks associated with over-medication and highlights the importance of individualizing treatment. Plus, hear tips on adherence and monitoring for optimal outcomes!
AI Snips
Chapters
Transcript
Episode notes
Patient Example: Lower Dose Consideration
- Michael is a 34-year-old teacher on 80 mg of lurasidone with persistent depressive symptoms and side effects.
- The hosts suggest considering lowering his dose to improve symptoms and reduce adverse effects.
40–60 mg Is The Optimal Window
- A dose-response meta-analysis of five RCTs found 40–60 mg/day of lurasidone optimally improved depression, anxiety, and disability.
- This optimal range sits well below the FDA's 120 mg max for bipolar depression.
Start Low, Trial 4 Weeks At 40–60 mg
- Start lurasidone at 20 mg and titrate to 40–60 mg, then give an adequate trial of about four weeks at that dose.
- Assess mood, anxiety, and function before considering careful dose increases if response is inadequate.